



Clinical trial results:

A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2016-000475-24 |
| Trial protocol | AT DE |
| Global end of trial date | 28 March 2024 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 18 October 2024 |
| First version publication date | 18 October 2024 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | AGMT_MM-2 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02891811 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | AGMT |
| Sponsor organisation address | Gentzgasse 60/21, Vienna, Austria, 1180 |
| Public contact | Daniela Wolkersdorfer, AGMT, +43 6626404412, d.wolkersdofer@agmt.at |
| Scientific contact | Richard Greil, AGMT, +43 6626404412, office@agmt.at |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 24 March 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 24 March 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 28 March 2024 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To show non-inferiority with respect to response rates between KTd and KRd: Overall response rate (ORR) are assessed according to International Myeloma Working Group (IMWG) criteria to determine the ORR in patients NDMM after receiving max 9 cycles induction therapy with either carfilzomib in combination with thalidomide and dexamethasone or carfilzomib in combination with lenalidomide and dexamethasone

Protection of trial subjects:

Anti-biotic, anti-viral, and anti-thrombosis pretreatment and prophylaxis was mandatory. Guidelines for dose modifications on case of toxicities were given. In general, concomitant medications and therapies necessary for supportive care and safety of the patient were allowed. The administration of any other anticancer agent or other concurrent investigational drug was not permitted. The inclusion of women of childbearing potential (WOCBP) and male subjects with pregnant or non-pregnant WOCBP had to follow specific recommendations for contraception and pregnancy testing. Furthermore, for all participating patients special counselling regarding use of thalidomide or lenalidomide had to be done prior to each treatment cycle.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 20 March 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Austria: 121 |
| Country: Number of subjects enrolled | Germany: 3 |
| Worldwide total number of subjects | 124 |
| EEA total number of subjects | 124 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---------------------------|-----|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 4 |
| From 65 to 84 years | 118 |
| 85 years and over | 2 |

Subject disposition

Recruitment

Recruitment details:

Between 20-Mar-2017 and 16-Dec-2021, 124 patients were enrolled in 16 sites in Austria and 2 sites in Germany. 1 patient withdrew consent shortly after randomization, did not receive any study treatment and is excluded from analysis.

Pre-assignment

Screening details:

Adult patients (≥ 18 years) with newly diagnosed, symptomatic MM not eligible or not willing to undergo autologous stem cell transplantation following induction and who are $<$ NYHA class III/IV, ECOG PS 0-1, CrCl $>$ 30ml/min, PN ≤ 2 (without pain).

Period 1

| | |
|------------------------------|-------------------------|
| Period 1 title | Induction |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---------------|
| Are arms mutually exclusive? | Yes |
| Arm title | KTd Induction |

Arm description:

Induction therapy for a maximum of 9 cycles

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Carfilzomib |
| Investigational medicinal product code | |
| Other name | Kyprolis |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Infusion |

Dosage and administration details:

Cycle 1: 20mg/m² on day 1+2, 27mg/m² on day 8, 9, 15 and 16; Cycle 2: 27mg/m² on day 1,2,8,9,15 and 16; Cycle 3-9: 56mg/m² on day 1, 8 and 15

| | |
|--|---------------|
| Investigational medicinal product name | Thalidomide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

100mg/day, day 1-28 (50mg in patients aged ≥ 75 years)

| | |
|--|---------------------------------|
| Investigational medicinal product name | Dexamethasone |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection/infusion, Tablet |
| Routes of administration | Infusion , Injection , Oral use |

Dosage and administration details:

40mg/week- day 1,8,15,22 (20mg in patients aged ≥ 75 years)

| | |
|------------------|---------------|
| Arm title | KRd Induction |
|------------------|---------------|

Arm description:

Induction therapy for a maximum of 9 cycles

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|----------------------------------|
| Investigational medicinal product name | Carfilzomib |
| Investigational medicinal product code | |
| Other name | Kyprolis |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Infusion |

Dosage and administration details:

Cycle 1: 20mg/m² on day 1+2, 27mg/m² on day 8, 9, 15 and 16; Cycle 2: 27mg/m² on day 1,2,8,9,15 and 16; Cycle 3-9: 56mg/m² on day 1, 8 and 15

| | |
|--|---------------|
| Investigational medicinal product name | Lenalidomide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

25mg/day, day 1-21

| | |
|--|---------------------------------|
| Investigational medicinal product name | Dexamethasone |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection/infusion, Tablet |
| Routes of administration | Infusion , Injection , Oral use |

Dosage and administration details:

40mg/week- day 1,8,15,22 (20mg in patients aged ≥75 years)

| Number of subjects in period 1^[1] | KTd Induction | KRd Induction |
|---|---------------|---------------|
| Started | 63 | 60 |
| Completed | 46 | 38 |
| Not completed | 17 | 22 |
| investigator's decision | 2 | 1 |
| severe AE/toxicity | 9 | 15 |
| progressive disease/death | 2 | 3 |
| patient's decision | 4 | 2 |
| dialysis-dependent | - | 1 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One patient withdrew consent shortly after randomization in KRd arm and did not receive any study treatment. This patient is excluded from analysis.

Period 2

| | |
|------------------------------|-------------------------|
| Period 2 title | Maintenance |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|--|----------------------------------|
| Arm title | K monotherapy |
| Arm description: Maintenance treatment with carfilzomib for a maximum period of 12 months. | |
| Arm type | Experimental |
| Investigational medicinal product name | Carfilzomib |
| Investigational medicinal product code | |
| Other name | Kyprolis |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Infusion |
| Dosage and administration details: day 1 and day 15 using the last tolerated dose for 12 cycles | |
| Arm title | Observation |
| Arm description: Observation for 12 months | |
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 2 | K monotherapy | Observation |
|---------------------------------------|---------------|-------------|
| Started | 42 | 42 |
| Completed | 28 | 26 |
| Not completed | 14 | 16 |
| investigator's decision | 2 | 2 |
| ongoing at primary endpoint analysis | 1 | 1 |
| progressive disease/death | 7 | 13 |
| severe AE/toxicity | 2 | - |
| patient's decision | 2 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | KTd Induction |
|-----------------------|---------------|

Reporting group description:

Induction therapy for a maximum of 9 cycles

| | |
|-----------------------|---------------|
| Reporting group title | KRd Induction |
|-----------------------|---------------|

Reporting group description:

Induction therapy for a maximum of 9 cycles

| Reporting group values | KTd Induction | KRd Induction | Total |
|---|---------------|---------------|-------|
| Number of subjects | 63 | 60 | 123 |
| Age categorical Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous Units: years | | | |
| median | 75 | 75 | |
| full range (min-max) | 58 to 84 | 55 to 84 | - |
| Gender categorical Units: Subjects | | | |
| Female | 31 | 24 | 55 |
| Male | 32 | 36 | 68 |

End points

End points reporting groups

| | |
|---|---------------|
| Reporting group title | KTd Induction |
| Reporting group description: Induction therapy for a maximum of 9 cycles | |
| Reporting group title | KRd Induction |
| Reporting group description: Induction therapy for a maximum of 9 cycles | |
| Reporting group title | K monotherapy |
| Reporting group description: Maintenance treatment with carfilzomib for a maximum period of 12 months. | |
| Reporting group title | Observation |
| Reporting group description: Observation for 12 months | |

Primary: Response

| | |
|--|----------|
| End point title | Response |
| End point description: Response in patients treated with KTd or KRd during induction therapy. Patients who received study medication for at least 4 weeks were evaluable for response. | |
| End point type | Primary |
| End point timeframe: Response assessment was done at day 1 of each cycle (except cycle 1) and at the end of K combination treatment | |

| End point values | KTd Induction | KRd Induction | | |
|-----------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 61 | 55 | | |
| Units: Subjects | | | | |
| stringent complete response (sCR) | 7 | 4 | | |
| complete response (CR) | 20 | 17 | | |
| very good partial response (VGPR) | 21 | 19 | | |
| partial response (PR) | 8 | 8 | | |
| minimal response (MR) | 3 | 2 | | |
| stable disease (SD) | 2 | 4 | | |
| progressive disease (PD) | 0 | 1 | | |

Statistical analyses

| | |
|---|------------------------|
| Statistical analysis title | Overall response rates |
| Statistical analysis description: Response rates were similar during induction therapy with KTd (91.8%) and KRd (87.3%), meeting the requirements for non-inferiority. | |

| | |
|---|--------------------------------|
| Comparison groups | KTd Induction v KRd Induction |
| Number of subjects included in analysis | 116 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[1] |
| Parameter estimate | Difference |
| Point estimate | -4.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -17 |
| upper limit | 7.1 |

Notes:

[1] - Non-inferiority is postulated if the CI of the differences does not cross 11%. CI was calculated using the Miettinen-Nurminen method

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All patients having received at least one dose of the study medication were followed for adverse events for at least 28 days after discontinuing study treatment or completion of study treatment.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Safety population |
|-----------------------|-------------------|

Reporting group description:

The safety population includes all enrolled patients who received at least one dose of the study treatment. SARs are assessed as related to carfilzomib.

| Serious adverse events | Safety population | | |
|---|-------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 86 / 123 (69.92%) | | |
| number of deaths (all causes) | 23 | | |
| number of deaths resulting from adverse events | 6 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bowen's disease | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Hypotension | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Embolism | | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypertensive crisis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thrombophlebitis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Circulatory collapse | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thrombosis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Deep vein thrombosis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Arterial stenosis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypertension | | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 123 (4.07%) | | |
| occurrences causally related to treatment / all | 2 / 5 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Asthenia | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pain | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Death | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Oedema | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Drug intolerance | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infusion site reaction | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hernia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Cystocele | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary congestion | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pleural effusion | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Psychiatric disorders | | | |
| Suicide attempt | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| C-reactive protein increased | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood creatine increased | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Injury, poisoning and procedural complications | | | |
| Accidental overdose | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infusion related reaction | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Fall | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wound haemorrhage | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiac failure | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences causally related to treatment / all | 7 / 8 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Sinus bradycardia | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Syncope | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Polyneuropathy | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Epilepsy | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Depressed level of consciousness | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peroneal nerve palsy | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Facial paralysis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombotic microangiopathy | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |

| | | | | |
|---|-----------------|--|--|--|
| Nausea | | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | | |
| occurrences causally related to treatment / all | 2 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vomiting | | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | | |
| occurrences causally related to treatment / all | 2 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enteritis | | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haematochezia | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal haemorrhage | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastritis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal haemorrhage | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatobiliary disorders | | | | |

| | | | |
|---|-----------------|--|--|
| Hepatic failure | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences causally related to treatment / all | 3 / 7 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Toxic epidermal necrolysis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Decubitus ulcer | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Drug reaction with eosinophilia and systemic symptoms | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 4 / 123 (3.25%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 1 | | |

| | | | | |
|---|-----------------|--|--|--|
| Urinary retention | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic kidney disease | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal failure | | | | |
| subjects affected / exposed | 3 / 123 (2.44%) | | | |
| occurrences causally related to treatment / all | 1 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal and connective tissue disorders | | | | |
| Spinal pain | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neck pain | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Back pain | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bone lesion | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rheumatoid arthritis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | |
|---|-------------------|--|--|
| Bone pain | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thoracic spinal stenosis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gouty arthritis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 15 / 123 (12.20%) | | |
| occurrences causally related to treatment / all | 11 / 16 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 4 / 123 (3.25%) | | |
| occurrences causally related to treatment / all | 2 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper respiratory tract infection | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| COVID-19 | | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diverticulitis | | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Influenza | | | | |
| subjects affected / exposed | 2 / 123 (1.63%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sinusitis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory tract infection | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infection | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Viral pericarditis | | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Febrile infection | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neuroborreliosis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Osteomyelitis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral myocarditis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacteraemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mastoiditis | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Hypocalcaemia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 2 / 123 (1.63%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cachexia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 123 (0.81%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 4 %

| Non-serious adverse events | Safety population | | |
|---|--------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 118 / 123 (95.93%) | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 12 / 123 (9.76%) | | |
| occurrences (all) | 20 | | |
| Hypotension | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences (all) | 8 | | |
| Thrombophlebitis | | | |

| | | | |
|--|-------------------|--|--|
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 7 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 63 / 123 (51.22%) | | |
| occurrences (all) | 110 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 44 / 123 (35.77%) | | |
| occurrences (all) | 71 | | |
| Pyrexia | | | |
| subjects affected / exposed | 19 / 123 (15.45%) | | |
| occurrences (all) | 29 | | |
| Pain | | | |
| subjects affected / exposed | 12 / 123 (9.76%) | | |
| occurrences (all) | 18 | | |
| Chills | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences (all) | 9 | | |
| Asthenia | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences (all) | 9 | | |
| Chest pain | | | |
| subjects affected / exposed | 7 / 123 (5.69%) | | |
| occurrences (all) | 7 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 7 / 123 (5.69%) | | |
| occurrences (all) | 7 | | |
| Oedema | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 7 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 23 / 123 (18.70%) | | |
| occurrences (all) | 29 | | |
| Cough | | | |

| | | | |
|------------------------------|-------------------|--|--|
| subjects affected / exposed | 13 / 123 (10.57%) | | |
| occurrences (all) | 15 | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 10 / 123 (8.13%) | | |
| occurrences (all) | 10 | | |
| Psychiatric disorders | | | |
| Sleep disorder | | | |
| subjects affected / exposed | 10 / 123 (8.13%) | | |
| occurrences (all) | 11 | | |
| Insomnia | | | |
| subjects affected / exposed | 9 / 123 (7.32%) | | |
| occurrences (all) | 12 | | |
| Investigations | | | |
| C-reactive protein increased | | | |
| subjects affected / exposed | 19 / 123 (15.45%) | | |
| occurrences (all) | 22 | | |
| Platelet count decreased | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences (all) | 27 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 7 / 123 (5.69%) | | |
| occurrences (all) | 18 | | |
| Nervous system disorders | | | |
| Polyneuropathy | | | |
| subjects affected / exposed | 22 / 123 (17.89%) | | |
| occurrences (all) | 27 | | |
| Tremor | | | |
| subjects affected / exposed | 15 / 123 (12.20%) | | |
| occurrences (all) | 17 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 11 / 123 (8.94%) | | |
| occurrences (all) | 12 | | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 8 / 123 (6.50%) | | |
| occurrences (all) | 9 | | |
| Headache | | | |

| | | | |
|--------------------------------------|-------------------|--|--|
| subjects affected / exposed | 14 / 123 (11.38%) | | |
| occurrences (all) | 16 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 20 / 123 (16.26%) | | |
| occurrences (all) | 33 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 17 / 123 (13.82%) | | |
| occurrences (all) | 34 | | |
| Neutropenia | | | |
| subjects affected / exposed | 11 / 123 (8.94%) | | |
| occurrences (all) | 17 | | |
| Leukopenia | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 8 | | |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 27 / 123 (21.95%) | | |
| occurrences (all) | 35 | | |
| Tinnitus | | | |
| subjects affected / exposed | 7 / 123 (5.69%) | | |
| occurrences (all) | 9 | | |
| Eye disorders | | | |
| Visual impairment | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 7 | | |
| Cataract | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 6 | | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 37 / 123 (30.08%) | | |
| occurrences (all) | 67 | | |
| Constipation | | | |
| subjects affected / exposed | 32 / 123 (26.02%) | | |
| occurrences (all) | 40 | | |
| Diarrhoea | | | |

| | | | |
|---|-------------------|--|--|
| subjects affected / exposed | 27 / 123 (21.95%) | | |
| occurrences (all) | 43 | | |
| Vomiting | | | |
| subjects affected / exposed | 14 / 123 (11.38%) | | |
| occurrences (all) | 21 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 7 | | |
| Dry mouth | | | |
| subjects affected / exposed | 6 / 123 (4.88%) | | |
| occurrences (all) | 7 | | |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 25 / 123 (20.33%) | | |
| occurrences (all) | 39 | | |
| Pruritus | | | |
| subjects affected / exposed | 9 / 123 (7.32%) | | |
| occurrences (all) | 11 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 18 / 123 (14.63%) | | |
| occurrences (all) | 22 | | |
| Arthralgia | | | |
| subjects affected / exposed | 18 / 123 (14.63%) | | |
| occurrences (all) | 25 | | |
| Muscle spasms | | | |
| subjects affected / exposed | 17 / 123 (13.82%) | | |
| occurrences (all) | 27 | | |
| Bone pain | | | |
| subjects affected / exposed | 10 / 123 (8.13%) | | |
| occurrences (all) | 15 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 9 / 123 (7.32%) | | |
| occurrences (all) | 12 | | |
| Myalgia | | | |

| | | | |
|--|--|--|--|
| subjects affected / exposed occurrences (all) | 7 / 123 (5.69%) 10 | | |
| Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all) Bronchitis subjects affected / exposed occurrences (all) Infection subjects affected / exposed occurrences (all) | 19 / 123 (15.45%) 20 14 / 123 (11.38%) 15 11 / 123 (8.94%) 14 8 / 123 (6.50%) 8 | | |
| Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) Hypokalaemia subjects affected / exposed occurrences (all) Hypocalcaemia subjects affected / exposed occurrences (all) | 17 / 123 (13.82%) 19 9 / 123 (7.32%) 9 7 / 123 (5.69%) 11 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|---|
| 31 January 2017 | Based on data from Biran et al. 2016, presented at ASH 2016, increased cardiotoxicity and thrombotic microangiopathy were seen in elderly patients receiving 70 mg carfilzomib in combination with dexamethasone and lenalidomide. Due to these observations, the dose and scheduling of carfilzomib was adapted for this trial. Also frail patients and those with an ECOG PS status ≥ 2 were excluded from this study. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/38895059>

<http://www.ncbi.nlm.nih.gov/pubmed/38425185>